Focus on the Hypoxia Pathway…

Hypoxia in tumors is closely associated with tumor aggressiveness and resistance to radio- and chemotherapeutic treatment. Therefore, reliable markers for hypoxia represent both valuable diagnostic markers and potential targets for investigation.

When oxygen becomes limited, prolyl hydroxylase is inhibited which leads to HIF-α accumulation and translocation to the nucleus. HIF-α then dimerizes with HIF-β and interacts with cofactors such as p300/CBP and the Pol II complex to activate the hypoxia-response elements (HRE), which activate transcription of various genes including VEGFA, GLUT1, and CA9.

tebu-bio has selected a panel of primary antibodies related to this pathway.

hypoxia pathway

A selection of 100% guaranteed research antibodies related to the Hypoxia pathway

 Need to select the most suitable to your research?

Take a look on our Hypoxia pathway sampler kit, the ideal product to select your antibody for your research project. This kitcontains trial size of antibodies specific for 7 proteins:

  • GTX101147 Heme Oxygenase 1
  • GTX127310 TWIST
  • GTX125971 ARD1A
  • GTX110585 NFkB p105/p50
  • GTX213110-01 Rabbit IgG (HRP)
  • GTX127309 HIF1 alpha
  • GTX113078 HIF2 alpha [N1N3-3]

Looking for a specific intracellular pathway?

We strive to provide you regularly with new and updated pathways to support you in your research. If you are looking for a specific pathway, don’t hesitate to contact us.

 

Trackbacks

  1. […] a previous post, we looked at the role of  HIF-1α  and HIF-2α in the hypoxia phenomenom. Metabolic […]

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

w

Connecting to %s

%d bloggers like this: